Weekly Paclitaxel and Trastuzumab in Metastatic Breast Cancer
Status:
Completed
Trial end date:
2009-12-01
Target enrollment:
Participant gender:
Summary
The 3 weekly combination of trastuzumab and paclitaxel has been approved for the treatment of
advanced breast cancer based on a large pivotal study. However, mono and combination
chemotherapy trials suggest that weekly paclitaxel has a better therapeutic index, especially
in the palliative setting. The present trial examines the efficacy and safety of weekly
paclitaxel over a limited duration combined with continued trastuzumab in HER2+ patients.